Comparable stake leader
Douglas M. Singer
SEC ownership of INTERPACE BIOSCIENCES, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001054102.
Disclosed value leader
Ampersand 2018 Limited Partnership
Comparable rows
1/6
Latest evidence
20 Jan 2026
- Public ticker
- IDXG on OTC
- Parsed ownership sources
-
13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Douglas M. Singer
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
1 of 6
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Douglas M. Singer
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
20 Jan 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001054102
- Issuer location
- Parsippany, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of INTERPACE BIOSCIENCES, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Douglas M. Singer
Disclosed value leader
Ampersand 2018 Limited Pa...
Comparable rows
1/6
Latest evidence
20 Jan 2026
13D/G
3/4/5
Lead comparable stake: 4.4%
5 rows are not safely comparable across share classes.
13D/G row: Douglas M. Singer
Quick read
Douglas M. Singer leads the comparable SEC ownership view at 4.4%.
1 of 6 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Douglas M. Singer's linked filing trail.
Comparable ownership
Top 1
Douglas M. Singer
4.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 6 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Douglas M. Singer |
13D/G
|
4.4%
|
$264,252
195,742 shares
|
-$42,260 | 10 Jan 2025 |
| Ampersand 2018 Limited Partnership |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$27,999,999
13,861,386 shares
|
— | 20 Jan 2026 |
| 1315 Capital II, L.P. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$19,000,000
9,405,941 shares
|
— | 20 Jan 2026 |
| Christopher McCarthy |
3/4/5
Chief Financial Officer
|
—
class O/S missing
|
$94,518
46,791 shares
|
— | 01 Feb 2024 |
| Thomas W. Burnell |
3/4/5
President & CEO, Director
|
—
mixed-class rows
|
—
235,855 shares
mixed-class rows
|
— | 21 May 2021 |
| Vijay Aggarwal |
3/4/5
Director
|
—
class O/S missing
|
—
28,000 shares
|
— | 01 Feb 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 18 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-5 of 5 reporting-owner rows connected to INTERPACE BIOSCIENCES, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
5
Largest Forms 3/4/5 holder
Ampersand 2018 Limited Partnership
Net 12M change
$0
Latest report
20 Jan 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Ampersand 2018 Limited Partnership | 10%+ Owner | $27,999,999 | Mixed | 20 Jan 2026 | ||
| 1315 Capital II, L.P. | 10%+ Owner | $19,000,000 | Mixed | 20 Jan 2026 | ||
| Christopher McCarthy | Chief Financial Officer | $94,518 | Mixed | 01 Feb 2024 | ||
| Thomas W. Burnell | President & CEO, Director | Mixed | 21 May 2021 | |||
| Vijay Aggarwal | Director | Mixed | 01 Feb 2022 |
Recent insider transactions for INTERPACE BIOSCIENCES, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| 1315 Capital II, L.P. | IDXG | Common Stock | Conversion of derivative security | 9,405,941 | 9,405,941 | 20 Jan 2026 | Direct | |||
| 1315 Capital II, L.P. | IDXG | Series C Convertible Preferred Stock | Conversion of derivative security | -100% | -19,000 | 0 | 20 Jan 2026 | Direct | ||
| Ampersand 2018 Limited Partnership | IDXG | Common Stock | Conversion of derivative security | 13,861,386 | 13,861,386 | 20 Jan 2026 | Direct | |||
| Ampersand 2018 Limited Partnership | IDXG | Series C Convertible Preferred Stock | Conversion of derivative security | -100% | -28,000 | 0 | 20 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.